To address critical issues in the development of new oncology drugs, Friends of Cancer Research and the Engelberg Center for Health Care Reform will co-host the seventh annual Conference on Clinical Cancer Research. This annual conference brings together leaders in cancer drug development from federal health and regulatory agencies, academic research, and the private sector for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies. This year’s conference will feature three panels that will propose unique approaches toward current challenges in drug development.
Agenda
-
November 21
-
Panel One: Potential Strategies for Non-Randomized Evaluation of New Drugs
9:00 am - 10:30 am
Deborah Armstrong Professor of Oncology - Johns Hopkins Kimmel Cancer CenterMace Rothenberg Senior Vice President, Clinical Development/Medical Affairs - PfizerRich Simon Chief, Biometric Research Branch - National Cancer InstituteJosh Sommer Executive Director - Chordoma FoundationGideon Blumenthal Clinical Team Leader - U.S. Food and Drug AdministrationRichard Pazdur Director, Office of Oncology Products - U.S. Food and Drug Administration -
Panel Two: Improving Evidence Developed From Population-Level Experience with Targeted Agents
10:45 am - 12:15 pm
Richard Schilsky Chief Medical Officer - American Society of Clinical OncologyJane Perlmutter Founder and President - Gemini GroupVincent Miller Chief Medical Officer - Foundation Medicine, Inc.Sam Nussbaum Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc.Dane Dickson Director of Clinical Science - MoIDX, Palmetto GBARichard Pazdur Director, Office of Oncology Products - U.S. Food and Drug Administration -
Panel Three: Consideration of Summary Review of Supplemental NDA/BLA Submissions in Oncology
1:45 pm - 3:15 pm
Rachel Sherman Principal, Drug and Biological Drug Products - Greenleaf Health LLCTatiana Prowell Breast Cancer Scientific Lead, Division of Oncology Products 1, Office of Hematology & Oncology Products - U.S. Food and Drug AdministrationKatherine Sugarman Senior Director, Global Regulatory Affairs, Oncology - Eli LillyLaurie Strawn Associate Director, Worldwide Regulatory Strategy - PfizerKannan Natarajan Senior Vice President and Global Head - Novartis PharmaceuticalsRaji Sridhara Acting Director, Division of Biometrics V - U.S. Food and Drug AdministrationRobyn Lim Senior Science Advisor - Health Canada -
Morning Keynote: A Path to 21st Century Cures
8:35 am - 9:00 am
Hon. Fred Upton Chairman - United States House of Representatives, Energy & Commerce Committee -
Lunch Keynote: State of FDA's Breakthrough Therapy Designation
12:45 pm
Janet Woodcock Director, Center for Drug Evaluation and Research - US Food and Drug Administration -
Welcome
8:30 am - 8:35 am
Ellen Sigal Chairperson and Founder - Friends of Cancer Research
-